Gastric Cancer Drug Development Shifting from Small Molecules to Monoclonal Antibodies

Worldwide: Our Business partners GBI Research’s new report “Frontier Pharma: Gastric Cancer - Early Stage Pipeline Innovation Shows Shift towards Targeted mAbs” analysis of the gastric cancer treatment pipeline, stratified by stage of development, molecule type and molecular target. It includes information on the current clinical and commercial landscape, and the composition of the gastric cancer therapeutics market in terms of dominant molecule types and targets, as well as highlighting current unmet needs.

While 99% of currently marketed gastric cancer drugs are small molecules, this dominance could give way to more innovative treatments in future, as the pipeline consists of 29% monoclonal antibodies (mAbs), according to business intelligence provider GBI Research.

The company’s latest report* states that there are currently 241 products in the gastric cancer pipeline, a number of which have different mechanisms of action and targets to the dominant marketed therapies.

Download Sample:https://marketreportscenter.com/reports/252384/frontier

Firas Nour, Associate Analyst for GBI Research, says that while Herceptin and Cyramza are the only mAbs currently on the market for gastric cancer, mAbs have shown strong clinical results and advantageous properties in numerous oncology indications, meaning they account for a relatively large proportion of many oncology pipelines.

Nour says: Data suggest that some biologics, such as mAbs, have more favorable risk profiles and, due to their higher target specificity, frequently perform more strongly in terms of both safety and efficacy than their synthetic counterparts. Moreover, the higher technological barrier for competitors to develop biosimilars can provide a further incentive.

However, while the diversification of therapeutic molecule types for marketed and pipeline products has opened new clinical and commercial opportunities, this in itself is not a guarantee of future success, and investment in product development as well as manufacturing facilities is significantly higher.

GBI Research also states that the innovative gastric cancer pipeline will allow the treatment space to become more diverse and less reliant on highly cytotoxic chemotherapy regimens, providing hope for sufferers who currently face very low survival rates.

Nour explains: 24% of gastric cancer products in active development are considered to be first-in-class, suggesting that the industry is pursuing novel approaches to treatment, and reducing the focus on established therapies.

First-in-class development can be highly lucrative if clinically successful, but is also associated with high risks, as clinical efficacy is certainly not guaranteed. Therefore, it must be considered that although having a high proportion of first-in-class products is a promising indicator in a pipeline, there is substantial variation in these products regarding their clinical promise and potential market impact.

Reasons to buy:

- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies
- Visualize the composition of the gastric cancer market in terms of dominant therapies for each patient subset along with their clinical and commercial standing. Unmet needs in the current market are highlighted to allow a competitive understanding of gaps in the current market.
- Analyze the gastric cancer pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target. There are promising signs in the pipeline that the industry is seeking novel approaches to treating gastric cancer.
- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
- Identify commercial opportunities in the gastric cancer deals landscape by analyzing trends in licensing and co-development deals and producing a list of gastric cancer therapies that are not yet involved in deals, and may be potential investment opportunities.Gastric Cancer Drug Development Shifting from Small Molecules to Monoclonal Antibodies

Scope:

- What is the pathophysiology of gastric cancer?
- How is gastric cancer diagnosed?
- What are the current treatment options?
- What are the common targets and mechanisms of action of pipeline therapies?
- Will the pipeline address unmet needs such as a lack of diverse treatment options for gastric cancer patients?
- What implications will the increased focus on targeted therapies have on the future of gastric cancer treatment?
- What are the most promising first-in-class targets for gastric cancer?
- Will the current first-in-class targets have a broader therapeutic potential across the industry?
- How do deal frequency and value compare between target families and molecule types?
- How do licensing and co-development deals compare between first-in-class and non-first-in-class profiles?

For More Details on report: https://marketreportscenter.com/reports/252384/frontier

Connect for more details:

Sam Collins
Market Reports Center
1-646-883-3044 (US)
+91- 20-41217796 (IND)
info@marketreportscenter.com
http://marketreportscenter.com
Follow us: Facebook Twitter Google + Linkedin Blogger

About Market Reports Center;
Market Reports Center is an e-commerce platform obliging the needs of knowledge workers, experts, professionals who are subject to market research information for their work, or to make strategic business decisions. We are dedicated to create a comprehensive offering of market research which is accurate, credible and affordable.
Market Reports Center currently has more than 1,20,000 plus titles and 30+ Publishers on our platform and growing consistently. We cover more than 35 industry verticals being: Automotive, Electronics, Manufacturing, Pharmaceuticals, Healthcare, Chemicals, Construction, Agriculture, Food, Beverages, Banking & Finance, Media and Government, Public Sector Studies.

House 421 Hudson Street New York, NY 10014, USA

This release was published on openPR.